Valsartan combined with vitamin D more efficiently reduces moderate proteinuria in IgA nephropathy
IgA nephropathy is a leading causes of chronic renal disease and end stage renal disease (ESRD). The risk of progression to ESRD is associated with the level of proteinuria, thus underlining the importance of adequate proteinuria control. A prospective, single-center, randomized controlled study followed patients with IgA nephropathy and moderate proteinuria of 1.0–3.0 g/24 h receiving valsartan, either alone or combined with calcitriol. While both groups achieved a significant decrease in proteinuria, the change was more prominent in the combination group. The incidence of adverse effects was similar, and no significant change in blood pressure, estimated glomerular filtration rate, serum calcium or serum potassium was observed.
